Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT00641381 2025-05-01

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
25 enrolled
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT01028716 2023-01-23

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 2 Terminated
46 enrolled 18 charts
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
NCT00068523 2020-07-27

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase NA Completed
10 enrolled
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00014235 2020-01-21

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Completed
160 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT00003196 2019-12-27

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Fred Hutchinson Cancer Center

Phase NA Completed
63 enrolled
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00005985 2017-11-29

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
213 enrolled
NCT00238368 2017-11-06

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
59 enrolled
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT01427881 2017-05-19

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
43 enrolled 14 charts
NCT01769911 2015-05-07

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase NA Withdrawn
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00008216 2014-06-06

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Columbia University

Terminated
48 enrolled
NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00003406 2013-03-26

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
30 enrolled
NCT00004232 2012-06-01

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Northwestern University

Phase 1 Completed
NCT00006379 2011-12-08

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Case Comprehensive Cancer Center

Phase 2 Completed
58 enrolled